Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications
| Autor: | Franz X. Roithinger, Monika Lechleitner, Ernst Pilger, Heinz Drexel, Bernhard Paulweber, Bernhard Metzler, Hans-Peter Haring, Alexander R. Rosenkranz, Hans Dieplinger, Thomas Weber, Stefan Kiechl, Thomas C. Wascher, Rainer Oberbauer, O. Traindl, Bernhard Föger, Sabine Horn, Bruno Watschinger, Hermann Toplak, Erich Pohanka, Bernhard Ludvik, Marianne Brodmann |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Pathology
medicine.medical_specialty Lipid Metabolism Disorder Statin Sekundärprävention medicine.drug_class Cardiology Lipid Metabolism Disorders Familial hypercholesterolemia 030204 cardiovascular system & hematology Vascular disease Atherosklerose Nephropathy 03 medical and health sciences Gefäßerkrankung 0302 clinical medicine Diabetes mellitus Humans Medicine Vascular Diseases 030212 general & internal medicine Intensive care medicine Hypolipidemic Agents Evidence-Based Medicine Primary prevention business.industry Secondary prevention General Medicine Evidence-based medicine LDL‑Cholesterin Atherosclerosis medicine.disease Treatment Outcome Austria Austrian Lipid Consensus Practice Guidelines as Topic LDL cholesterol Primärprävention Metabolic syndrome business |
| Zdroj: | Wiener Klinische Wochenschrift |
| ISSN: | 1613-7671 0043-5325 |
| DOI: | 10.1007/s00508-016-0993-x |
| Popis: | Summary In 2010, eight Austrian medical societies proposed a joint position statement on the management of metabolic lipid disorders for the prevention of vascular complications. An updated and extended version of these recommendations according to the current literature is presented, referring to the primary and secondary prevention of vascular complications in adults, taking into consideration the guidelines of other societies. The “Austrian Lipid Consensus – 2016 update” provides guidance for individualized risk stratification and respective therapeutic targets, and discusses the evidence for reducing vascular endpoints with available lipid-lowering therapies. Furthermore, specific management in key patient groups is outlined, including subjects presenting with coronary, cerebrovascular, and/or peripheral atherosclerosis; diabetes mellitus and/or metabolic syndrome; nephropathy; and familial hypercholesterolemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink